3 Bidders For Stake In Polish Drug Firm
Poland's Treasury Ministry has shortlisted three large foreign companiesin a tender for at least 10% of the state-owned drugmaker Polfa Poznan, according to Reuters. Although the Treasury Ministry's press office declined to confirm the report, it is believed that the shortlist includes Nycomed, Glaxo Wellcome and Bristol Myers Squibb.
Reuters also reports that investors are ready to pay between $150 million and $250 million for a majority stake in Polfa Poznan, with final bids to be submitted by end-August. A spokesman for the Polish company would only confirm that the firm was in talks with foreign groups and that privatization should be completed by the end of the year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze